Consulting Services
For Investors
Products
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
BioPharma and Tech News

Contact Us

Search

Orforglipron

Obesity Weekly News

Obesity Weekly News - September 9th 2025

Obesity Updates: WHO EML GLP-1s, Orforglipron P3, Korea MOU and More…

Obesity Weekly News

Obesity Weekly News - September 2nd 2025

Viking’s Crash, Orforglipron’s Big Win, Wegovy vs Tirzepatide, Saxenda Generic…

Obesity Weekly News

Obesity Weekly News - August 26th 2025

Viking’s Crash, Orforglipron’s Rise, Semaglutide CV Data, SlimBiome Deal &…

Obesity Weekly News

Obesity Weekly News - August 12th 2025

Obesity Update: Ascletis’ ASC30, Hanmi’s CRF2 Breakthrough, Orforglipron’s…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Rare Disease News
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Lucid Diligence Brief: Angitia Biopharmaceuticals $130 million Series D
Vaccines Video Recap—February 6, 2026
Respiratory Video Recap—February 6, 2026
Public Health Today—February 6, 2026
Vaccines Today—February 6, 2026

Tags

AA Signature Abbott Abeona Therapeutics ACTH-dependent Cushing’s Adrenal disorders AI in ophthalmology C4 Therapeutics CD19 CD19 CAR-T chronic obstructive pulmonary disease companion diagnostics CVD DYNE-251 Enanta ERβ ligands federated learning graphene devices Growth hormone deficiency HGPS IVUS JASCAYD Kesimpta Lexeo Therapeutics LGMD2i MedinCell methotrexate neuromuscular disease Novo Medi Sciences One Medical Organoids Parkway Radiology Partners Health Management Pascal pericarditis Phase 2 protocol-based HTN diabetes care Rein Therapeutics Semble sleep and brain health syndax pharmaceuticals SynKIR-110 talkspace University of Oslo Verily warrants

Archives

Archives

1
2

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Lucid Diligence Brief: Angitia Biopharmaceuticals $130 million Series D
Vaccines Video Recap—February 6, 2026
Respiratory Video Recap—February 6, 2026
Public Health Today—February 6, 2026
Vaccines Today—February 6, 2026

TAGS

AA Signature Abbott Abeona Therapeutics ACTH-dependent Cushing’s Adrenal disorders AI in ophthalmology C4 Therapeutics CD19 CD19 CAR-T chronic obstructive pulmonary disease companion diagnostics CVD DYNE-251 Enanta ERβ ligands federated learning graphene devices Growth hormone deficiency HGPS IVUS JASCAYD Kesimpta Lexeo Therapeutics LGMD2i MedinCell methotrexate neuromuscular disease Novo Medi Sciences One Medical Organoids Parkway Radiology Partners Health Management Pascal pericarditis Phase 2 protocol-based HTN diabetes care Rein Therapeutics Semble sleep and brain health syndax pharmaceuticals SynKIR-110 talkspace University of Oslo Verily warrants

Consulting Services
For Investors
Products
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy